

FORM 51 – 102F3
MATERIAL CHANGE REPORT

Item 1: Name and Address of Company

BioMark Diagnostics Inc. (“the Issuer”)
165 – 10551 Shellbridge Way
Richmond, BC V6X 2W8

Item 2: Date of Material Change

December 31st, 2019

Item 3: News Release

A news release was issued and disseminate on December 31st, 2019 and filed on SEDAR (www.sedar.com). A copy of the news release is attached as Schedule “A” hereto.

Item 4: Summary of Material Change

The issuer announced addition of distinguished experts to its scientific and medical advisory team. This new group of advisors will further strengthen our team and support our upcoming commercialization initiatives.

An incentive plan was approved by Board of Directors that consisted of aggregated 3,795,000 stock options exercisable at 30 cents under BioMark’s new option plan that was approved at the Annual General Meeting held on December 20, 2019. The options were issued to existing and new appointed scientific and medical advisors, consultants, directors and management.

Dr. Ian Smith is no longer on the Board of Directors. BioMark wishes to thank Dr. Ian Smith for his time with the company.

Item 5: Full Description of Material Change

Please see attached Schedule “A”

Item 6: Reliance on subsection 7.1(2) of National Instrument 51-102

Not applicable

Item 7: Omitted Information

None

Item 8: Executive Officer

Rashid Ahmed Bux, President & CEO

Telephone: 604.370.0779

Email: info@biomarkdiagnostics.com

Item 9: Date of Report

December 31st, 2019



165 – 10551 Shellbridge Way
Richmond, BC, V6X 2W8

BIOMARK ANNOUNCES APPOINTMENT OF SCIENTIFIC AND MEDICAL ADVISORS, GRANT OF STOCK OPTIONS AND CHANGES IN BOARD OF DIRECTORS

Vancouver, British Columbia – (December 31, 2019) – BioMark Diagnostics Inc. (“BioMark”) (CSE: BUX) (FSE: 20B) (OTCMKTS: BMKDF) is pleased to announce addition of distinguished experts to its scientific and medical advisory team. This new group of advisors will further strengthen our team and support our upcoming commercialization initiatives. Announcements relating to the appointment to each adviser will be made through appropriate news release.

“Over the past few months our new advisors have provided BioMark with excellent counsel on how to fine tune our clinical trial protocol(s) and opened new opportunities for global collaboration. As advisors, they will participate in scientific planning, research design, presenting to key medical opinion leaders and evaluate our commercialization as strategy” says Rashid Ahmed, President and CEO.

An incentive plan was approved by Board of Directors that consisted of aggregated 3,795,000 stock options exercisable at 30 cents under BioMark’s new option plan that was approved at the Annual General Meeting held on December 20, 2019. The options will be issued as incentive to existing and newly appointed scientific and medical advisors, consultants, directors and management. These stock options are governed by the Stock Option Plan of the Corporation.

Dr. Ian Smith is no longer on the Board of Directors. BioMark wishes to thank Dr. Ian Smith for his time with the company.

About BioMark Diagnostics Inc.

BioMark is developing proprietary, non-invasive, and accurate cancer diagnostic solutions which can help detect, monitor and assess treatment for cancer early and cost effectively. The technology can also be used for measuring response to treatment and potentially for serial monitoring for cancer survivors.

Further information about BioMark is available under its profile on the SEDAR website www.sedar.com and on the CSE website <https://thecse.com/>.

For further information on BioMark, please Contact:

Rashid Ahmed Bux

President & CEO

BioMark Diagnostics Inc.

Tel. 604-370-0779

Email: info@biomarkdiagnostics.com

Company website: www.biomarkdiagnostics.com

Forward-Looking Information:

This press release may include forward-looking information within the meaning of Canadian securities legislation, concerning the business of BioMark. Forward-looking information is based on certain key expectations and assumptions made by the management of BioMark. Although BioMark believes that the expectations and assumptions on which such forward-looking information is based are reasonable, undue reliance should not be placed on the forward-looking information because BioMark can give no assurance that they will prove to be correct. Forward-looking statements contained in this press release are made as of the date of this press release. BioMark disclaims any intent or obligation to update publicly any forward-looking information, whether as a result of new information, future events or results or otherwise, other than as required by applicable securities laws.

The CSE has not reviewed, approved or disapproved the content of this press release.